A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer.
BJU International, Supplement.
Times cited: 54
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials.
Journal of Clinical Oncology.
Times cited: 537